Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27436150 | 0.89 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| SCHEMBL14388593 | 0.89 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| SCHEMBL887851 | 0.88 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| SCHEMBL1517629 | 0.88 | TK1 (0.44) | TK1LMNATSHRALBPKM | |
| SCHEMBL15321521 | 0.87 | TK1 (0.34) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL7760372 | 0.87 | TK1 (0.35) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL28249854 | 0.87 | TK1 (0.42) | TK1LMNATSHRALBPKM | |
| Phosphoric Acid SCHEMBL8091428 | 0.85 | TYMP (0.42) | TK1ALBPKM | |
| SCHEMBL5611651 | 0.85 | TK1 (0.41) | TK1LMNATSHRALBPKM | |
| SCHEMBL8470852 | 0.85 | TK1 (0.41) | TK1LMNAALBPKMBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790196-A | Reversibly blocked nucleoside analogs and uses thereof | 考利达基因组股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| EP-2331106-B1 | NUCLEOSIDE ANALOGUES USEFUL AS POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS | IMP INNOVATIONS LTD (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20110236312-A1 | NUCLEOSIDE ANALOGUES USEFUL AS POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-09-29 | — | — | US | disclosed |
| EP-2331106-A1 | NUCLEOSIDE ANALOGUES USEFUL AS POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS | Imperial Innovations Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010023457-A1 | NUCLEOSIDE ANALOGUES USEFUL AS POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236312-A1 | NUCLEOSIDE ANALOGUES USEFUL AS POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS | TYMP, SLC29A1, NT5C3B | TK1 16/4885LMNA 3864/4885TSHR 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.